Suppr超能文献

用于肝细胞癌鉴别诊断的Hep par 1抗体染色:使用组织微阵列和传统组织切片检测676例肿瘤。

Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.

作者信息

Fan Zhen, van de Rijn Matt, Montgomery Kelli, Rouse Robert V

机构信息

Department of Pathology L235, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305-5324, USA.

出版信息

Mod Pathol. 2003 Feb;16(2):137-44. doi: 10.1097/01.MP.0000052103.13730.20.

Abstract

A well-characterized positive marker for hepatocellular differentiation would be a useful tool for the diagnosis of hepatocellular carcinoma (HCC). The recently commercially available Hep Par 1 antibody (clone OCH1E5.2.10) has been reported to be a sensitive marker for HCC in paraffin embedded sections. Of non-hepatocellular tumors, occasional carcinomas have been reported to stain, most frequently gastric adenocarcinomas. This study further evaluated the staining of this antibody on a large number of neoplasms using tissue microarray technology as well as conventional tissue sections. Six hundred seventy-six tumors, including 19 cases of HCC, were tested. Eighteen of 19 cases of HCC were positive, 3 showing <5% staining. Two cases negative on the array showed focal staining when whole tissue sections from the same tumors were used. 16 of 34 cases of gastric carcinomas gave positive reactions, 4 of these showed less than 5% staining. Staining of gastric carcinomas was not limited to signet ring-type carcinomas or to areas of hepatoid differentiation. Only 1 of 11 cases of cholangiocarcinoma showed focal staining. We also noted several other tumors to stain occasionally, including adrenal cortical carcinoma (3/13), yolk sac tumor (2/9), colonic adenocarcinoma (8/106), lung carcinoma (3/52), ovarian carcinoma (5/48), and endocervical adenocarcinoma (1/5). We did not observe staining in pancreatic carcinoma (11), renal cell carcinoma (36), breast carcinoma (85), melanoma (25), or mesothelioma (5). This study supports Hep Par 1 as a useful marker in the differential diagnosis of HCC, but with significant limitations. Cautious use of this antibody in a panel with other positive (alpha fetoprotein, CD10, polyclonal carcinoembryonic antigen) and negative (epithelial membrane antigen, monoclonal carcinoembryonic antigen, CD15) markers of hepatocellular differentiation may aid in the accurate diagnosis of HCC.

摘要

一种特征明确的肝细胞分化阳性标志物将是诊断肝细胞癌(HCC)的有用工具。最近市售的Hep Par 1抗体(克隆OCH1E5.2.10)据报道是石蜡包埋切片中HCC的敏感标志物。在非肝细胞肿瘤中,偶尔有报道称某些癌会染色,最常见的是胃腺癌。本研究使用组织芯片技术以及传统组织切片,进一步评估了该抗体在大量肿瘤上的染色情况。共检测了676个肿瘤,包括19例HCC。19例HCC中有18例呈阳性,3例染色<5%。芯片检测为阴性的2例,当使用同一肿瘤的全组织切片时显示局灶性染色。34例胃癌中有16例呈阳性反应,其中4例染色<5%。胃癌的染色不限于印戒型癌或肝样分化区域。11例胆管癌中仅1例显示局灶性染色。我们还注意到其他几种肿瘤偶尔也会染色,包括肾上腺皮质癌(3/13)、卵黄囊瘤(2/9)、结肠腺癌(8/106)、肺癌(3/52)、卵巢癌(5/48)和宫颈内膜腺癌(1/5)。我们在胰腺癌(11例)、肾细胞癌(36例)、乳腺癌(85例)、黑色素瘤(25例)或间皮瘤(5例)中未观察到染色。本研究支持Hep Par 1作为HCC鉴别诊断中的有用标志物,但存在显著局限性。谨慎地将该抗体与其他肝细胞分化的阳性(甲胎蛋白、CD10、多克隆癌胚抗原)和阴性(上皮膜抗原、单克隆癌胚抗原、CD15)标志物联合使用,可能有助于HCC的准确诊断。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验